European Academy of Allergy and Clinical Immunology

European Academy of Allergy and Clinical Immunology: Launch of the EAACI Guidelines for the Use of Biologicals in Patients With Severe Asthma

Retrieved on: 
Monday, June 8, 2020
Medical specialties, Medicine, European Academy of Allergy and Clinical Immunology, RTT, Allergy

ZRICH, June 8, 2020 /PRNewswire/ -- EAACI has launched its Guidelines for the use of Biologicals in Patients with Severe Asthma at the EAACI Digital Congress 2020.

Key Points: 
  • ZRICH, June 8, 2020 /PRNewswire/ -- EAACI has launched its Guidelines for the use of Biologicals in Patients with Severe Asthma at the EAACI Digital Congress 2020.
  • Prof. Marek Jutel, EAACI President began by highlighting the significant burden of severe asthma on patients, families and healthcare systems.
  • Oscar Palomares, Complutense University of Madrid, Past Chair of EAACI Biologicals Working Group, current EAACI ExCom member and Biologicals Guidelines Project Co-Chair.
  • The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956.

Blueprint Medicines Presents Updated Part 1 Data from PIONEER Trial of Avapritinib Showing Robust Reductions in Cutaneous Disease Symptoms in Patients with Indolent Systemic Mastocytosis

Retrieved on: 
Saturday, June 6, 2020
Medicine, Medical specialties, Immune system disorders, Organ systems, Medical terminology, Mastocytosis, Disease, European Academy of Allergy and Clinical Immunology, Medical sign, Psychiatric diagnosis, Draft:European Competence Network on Mastocytosis

"The updated PIONEER trial data showed that patients treated with avapritinib had clinically meaningful reductions in mediator symptoms, patient-reported quality of life and mast cell burden across multiple measures.

Key Points: 
  • "The updated PIONEER trial data showed that patients treated with avapritinib had clinically meaningful reductions in mediator symptoms, patient-reported quality of life and mast cell burden across multiple measures.
  • With further evidence that these reductions deepen over time, avapritinib has the potential to provide important clinical benefits to patients with this debilitating disease."
  • "Avapritinib was specifically designed to potently target the underlying disease driver of systemic mastocytosis and has the potential to fundamentally change the treatment of this disease."
  • Updated data on disease symptoms through 24 weeks and new skin assessment results were reported in the EAACI presentation.

Long-term (48-week) Data Show Treatment with Berotralstat Provides Robust and Durable Reductions in HAE Attacks and Improvements in Quality of Life Scores

Retrieved on: 
Saturday, June 6, 2020
European Academy of Allergy and Clinical Immunology

Berotralstat was also safe and generally well-tolerated over 48 weeks in both APeX-2 and APeX-S.

Key Points: 
  • Berotralstat was also safe and generally well-tolerated over 48 weeks in both APeX-2 and APeX-S.
  • The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress.
  • The most common adverse event was the common cold, which occurred with similar frequency in berotralstat and placebo patients.
  • Drug-related serious adverse events occurred in three of 342 subjects (0.9 percent) and resolved after stopping or interrupting berotralstat dosing.

New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the Long-Term Safety and Efficacy of TAKHZYRO® (lanadelumab) in Reducing Hereditary Angioedema Attacks

Retrieved on: 
Saturday, June 6, 2020
Biotechnology, Health, Genetics, Pharmaceutical, Clinical trials, Medical specialties, Medicine, RTT, Organ systems, Complement deficiency, Hereditary angioedema, Serpinopathies, Angioedema, Hae, European Academy of Allergy and Clinical Immunology, Lanadelumab, Preventive healthcare

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced findings from two new interim analyses of data from the Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study Open-label Extension (OLE).

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced findings from two new interim analyses of data from the Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study Open-label Extension (OLE).
  • The data are being presented at the 2020 European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress.
  • The HELP Study OLE analyses add to the evidence that supports TAKHZYRO as a leading option in preventive HAE treatments.
  • Rollover patients received a dose of 300 mg TAKHZYRO on Day 0 and then every two weeks after their first attack.

DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020

Retrieved on: 
Thursday, June 4, 2020
Medical specialties, Medicine, CAC Mid 60, DBV Technologies, European Academy of Allergy and Clinical Immunology, DBV, Allergy

Food and Drug Administration

Key Points: 
  • Food and Drug Administration
    DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that seven abstracts, including four late breakers, highlighting new data from the Companys pre-clinical and clinical food allergy programs were accepted at the European Academy of Allergy & Clinical Immunology (EAACI) Digital Congress, June 6-8, 2020.
  • The data we are presenting at this years digital EAACI congress highlight potential applications of epicutaneous immunotherapy across patient populations as well as new insights into promising cellular pathways for biomarker identification, said Pharis Mohideen, M.D., Chief Medical Officer of DBV Technologies.
  • These presentations highlight the breadth of research DBV is conducting on the science and impact of food allergy as part of our commitment to improving the lives of patients through innovative potential treatments like epicutaneous immunotherapy.
  • Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

AllerGenis Announces Presentations at EAACI Digital Congress 2020

Retrieved on: 
Thursday, June 4, 2020
Biotechnology, Genetics, Health, Clinical trials, Medical specialties, Medicine, Immunology, European Academy of Allergy and Clinical Immunology, Immunologic tests, Allergy, Epitope mapping

Data-driven food allergy diagnostics company, AllerGenis LLC, today announced its activities at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress 2020, being held virtually from June 6th through 8th.

Key Points: 
  • Data-driven food allergy diagnostics company, AllerGenis LLC, today announced its activities at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress 2020, being held virtually from June 6th through 8th.
  • AllerGenis will have two presentations at the Congress, which are detailed below.
  • AllerGenis proprietary epitope mapping technology is based on immunological research by Dr. Sampson and leverages Genispheres expertise in improving sensitivity of diagnostic tests.
  • AllerGenis is creating the largest food allergy knowledge base populated by individual patient epitope signatures derived from epitope mapping, clinical history, and patient-reported outcomes to gain clinical insights.

New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented at EAACI 2020 Congress

Retrieved on: 
Monday, June 1, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Immunology, Medicine, Food allergies, Allergology, Respiratory diseases, RTT, Immune system, European Academy of Allergy and Clinical Immunology, Peanut allergy, Allergen immunotherapy, Allergy

These data will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress to be held from June 6-8.

Key Points: 
  • These data will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress to be held from June 6-8.
  • PALFORZIA is approved for use in the United States in patients with a confirmed diagnosis of peanut allergy.
  • In Europe, Aimmune has a marketing authorization application for AR101 (PALFORZIA) under review with the European Medicines Agency (EMA).
  • PALFORZIA is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.

BioCryst to Present New Berotralstat Data at European Academy of Allergy and Clinical Immunology Digital Congress

Retrieved on: 
Tuesday, May 26, 2020
Medical specialties, Complement deficiency, RTT, Health, Medicine, European Academy of Allergy and Clinical Immunology, BioCryst Pharmaceuticals, Angioedema, Hereditary angioedema, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., May 26, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present new data on berotralstat (BCX7353), an oral, once-daily therapy under regulatory review in the United States, Japan and the European Union for the prevention of hereditary angioedema (HAE) attacks, at the upcoming digital congress of the European Academy of Allergy and Clinical Immunology (EAACI) June 6-8.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., May 26, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present new data on berotralstat (BCX7353), an oral, once-daily therapy under regulatory review in the United States, Japan and the European Union for the prevention of hereditary angioedema (HAE) attacks, at the upcoming digital congress of the European Academy of Allergy and Clinical Immunology (EAACI) June 6-8.
  • EAACI plans to make content from the congress available at 9:00a CET on June 6.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties.

AB Science announces that the European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted its phase 3 study results with masitinib in severe asthma to be delivered as a late breaking oral presentation

Retrieved on: 
Thursday, May 7, 2020
Medical specialties, Medicine, Immunology, European Academy of Allergy and Clinical Immunology, Respiratory diseases, Asthma, Allergy

EAACI is one of the most prestigious academic meetings for pulmonary medicine and the worlds largest congress specializing in the field of allergy and clinical immunology.

Key Points: 
  • EAACI is one of the most prestigious academic meetings for pulmonary medicine and the worlds largest congress specializing in the field of allergy and clinical immunology.
  • Presented abstract texts will also be published on the EAACI Media Library and in the official EAACI journal Allergy after the congress.
  • Professor Lavinia Davidescu said: Unlike other drugs for severe asthma, masitinib targets the dual mechanisms of mast cell-related asthma pathophysiology and PDGFR-related airway remodeling.
  • Masitinib is therefore capable of simultaneously modulating independent mechanisms of asthma pathophysiology, which is an attractive therapeutic strategy for severe asthma.

AnaptysBio Announces Second Quarter 2019 Financial Results and Provides Pipeline Updates

Retrieved on: 
Thursday, August 8, 2019
Health, Medicine, Drug discovery, European Academy of Allergy and Clinical Immunology, Clinical trial, Igor P. Kaidashev, Mepolizumab

In June 2019, AnaptysBio presented full data from its Phase 2a proof-of-concept clinical trial of etokimab in adult patients with severe eosinophilic asthma at the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress.

Key Points: 
  • In June 2019, AnaptysBio presented full data from its Phase 2a proof-of-concept clinical trial of etokimab in adult patients with severe eosinophilic asthma at the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress.
  • The study is designed to assess different dose levels and dosing frequencies of subcutaneously-administered etokimab, with top-line data expected in the fourth quarter of 2019.
  • AnaptysBio is conducting a randomized, placebo-controlled Phase 2 trial in approximately 100 adult patients with chronic rhinosinusitis with nasal polyps, also referred to as the ECLIPSE trial.
  • The Company anticipates interim top-line data from the ECLIPSE trial in the fourth quarter of 2019.